

# CITATION REPORT

List of articles citing

Fracture incidence after 3 years of aromatase inhibitor therapy

DOI: 10.1093/annonc/mdu008

Annals of Oncology, 2014, 25, 843-847.

**Source:** <https://exaly.com/paper-pdf/58226749/citation-report.pdf>

**Version:** 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Frakturrisiko nach drei Jahren Aromataseinhibition. <i>Im Focus Onkologie</i> , <b>2014</b> , 17, 37-37	0	
31	Frakturrisiko nach drei Jahren Aromataseinhibition. <i>Gynäkologie + Geburtshilfe</i> , <b>2014</b> , 19, 20-20	0	
30	Fracture incidence after 3 years of aromatase inhibitor therapy <i>Annals of Oncology</i> , <b>2014</b> , 25, 1665-6	10.3	
29	Reply to the letter to the editor Fracture incidence after 3 years of aromatase inhibitor therapy by Laurent et al. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1666-7	10.3	
28	The dilemmas of breast cancer treatment and increased fracture risk by Malik. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1664-5	10.3	4
27	The dilemmas of breast cancer treatment and increased fracture risk. <i>Annals of Oncology</i> , <b>2014</b> , 25, 1664-5	10.3	1
26	Screening for osteoporosis after breast cancer: for whom, why and when. <i>Maturitas</i> , <b>2014</b> , 79, 343-8	5	10
25	Secondary osteoporosis: pathophysiology & diagnosis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 28, 911-35	6.5	37
24	Impact of aromatase inhibitor treatment on vertebral morphology and bone mineral density in postmenopausal women with breast cancer. <i>Menopause</i> , <b>2016</b> , 23, 33-9	2.5	11
23	Association of Quality and Quantity of Bone Metastases and Computed Tomography Volumetric Bone Mineral Density With Prevalence of Vertebral Fractures in Breast Cancer Patients. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, 402-409	3	9
22	Differentiating the Causes of Spontaneous Rib Fracture After Breast Cancer. <i>Clinical Breast Cancer</i> , <b>2016</b> , 16, 431-436	3	10
21	AI-related BMD variation in actual practice conditions: A prospective cohort study. <i>Endocrine-Related Cancer</i> , <b>2016</b> , 23, 303-12	5.7	4
20	Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study. <i>Bone</i> , <b>2017</b> , 97, 147-152	4.7	21
19	A Focused Review of Safety Considerations in Cancer Rehabilitation. <i>PM and R</i> , <b>2017</b> , 9, S415-S428	2.2	48
18	Evaluation and management of skeletal disease in cancer care. <i>Critical Reviews in Oncology/Hematology</i> , <b>2017</b> , 120, 217-226	7	8
17	Adverse bone effects of medications used to treat non-skeletal disorders. <i>Osteoporosis International</i> , <b>2017</b> , 28, 2741-2746	5.3	14
16	Osteoporosis management in patients with breast cancer: EMAS position statement. <i>Maturitas</i> , <b>2017</b> , 95, 65-71	5	36

15	Therapeutic Bone-Modifying Agents in the Nonmetastatic Breast Cancer Setting: The Controversy and a Value Assessment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , <b>2017</b> , 37, 116-122	7.1	0
14	Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. <i>European Journal of Cancer</i> , <b>2018</b> , 96, 82-90	7.5	19
13	Causes of low peak bone mass in women. <i>Maturitas</i> , <b>2018</b> , 111, 61-68	5	12
12	Effects on the Skeleton from Medications Used to Treat Nonskeletal Disorders. <b>2018</b> , 482-486		
11	Secondary Osteoporosis. <b>2019</b> , 253-269		2
10	Breast cancer treatment and its effects on aging. <i>Journal of Geriatric Oncology</i> , <b>2019</b> , 10, 346-355	3.6	29
9	Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study. <i>Oncologist</i> , <b>2019</b> , 24, 1432-1438	5.7	7
8	Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. <i>Reumatologia Clínica (English Edition)</i> , <b>2019</b> , 15, 211-217	0.1	
7	Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology, The</i> , <b>2019</b> , 20, 339-351	21.7	106
6	Impact of an osteoporosis specialized unit on bone health in breast cancer survivals treated with aromatase inhibitors. <i>Reumatologia Clínica</i> , <b>2019</b> , 15, 211-217	0.9	2
5	Molecular mechanisms and clinical management of cancer bone metastasis. <i>Bone Research</i> , <b>2020</b> , 8, 30	13.3	33
4	Effects on the skeleton from medications used to treat nonskeletal disorders. <b>2021</b> , 1061-1068		
3	From Theory to Practice: Bone Health in Women with Early Breast Cancer Treated with Aromatase Inhibitors. <i>Current Oncology</i> , <b>2021</b> , 28, 1067-1076	2.8	1
2	Pathophysiology and Epidemiology of Osteoporosis. <b>2020</b> , 9-20		
1	Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.		0